Skip to main content
S&P 5007,688.62+1.58%DOW53,356.12+3.03%NASDAQ25,736.51+1.44%BTC$79,572.00+1.69%ETH$2,385.58+3.00%GOLD$4,124.50+1.26%OIL$89.86+1.97%
Smart Investors Daily
SID Premium
AD

OTC · ADIA

Adia Nutrition, Inc.

Financial Services · Shell Companies

$0.06

Down-$0.06 (-47.46%)

Updated Nov 5, 2026, 1:24 PM

SID Score

4.8/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
19.82M
P/E ratio
-26,250
Dividend yield
0.00%
52-week range
$0.02 – $0.28
Volume
41.54K
Avg. volume
57.23K

Price performance · ADIA

ADIA price history

1M range · 0 trading sessions · Daily adjusted prices

ADIA does not have enough price history for the selected period.

Data unavailable

The requested market data was not found.

Latest ADIA news

The latest Smart Investors Daily articles mentioning ADIA.

Stock researchCompany · Overview

ADIA research

Overview

Company profile and research snapshot.

Company profile

ADIA NUTRITION INC

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
—
Implied upside
—
Analysts
—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Oct 26, 2026

Adia Med Reports No Serious Adverse Events in First Cohort of Pediatric Autism Study; Enrollment Continues

No serious adverse events reported in either study arm; enrollment and participant follow-up continueWinter Park, Florida--(Newsfile Corp. - October 26, 2026) - Adia Med Inc. (OTCQB: ADIA) today reported interim safety observations from the first cohort of its randomized Phase 1/2 investigational study in children with autism spectrum disorder (ASD). Investigators reported no serious adverse events in either study arm and no events requiring reporting to the Institutional Review Board (IRB)....

Yahoo · Oct 20, 2026

Adia Med Sells 7% Economic Interest in Adia Labs to CEO Larry Powalisz for $350,000 in Cash

Winter Park, Florida--(Newsfile Corp. - October 20, 2026) - Adia Med, Inc. (OTCQB: ADIA) today announced that its Chief Executive Officer, Larry Powalisz, purchased a 7% economic interest in Adia Labs LLC for $350,000 in cash. Under the completed Membership Interest Purchase Agreement, Powalisz purchased seven membership units at $50,000 per unit. The Company has filed a Current Report on Form 8-K relating to the transaction.Adia Med Sells 7% Economic Interest in Adia Labs to CEO Larry Powalisz.

Yahoo · Oct 13, 2026

Adia Med Fully Repays Related-Party Credit Facility, Strengthening Its Financial Position

Full repayment eliminates the Company's unsecured revolving credit facility and simplifies its remaining obligationsWinter Park, Florida--(Newsfile Corp. - October 13, 2026) - Adia Med, Inc. (OTCQB: ADIA) (the "Company") today announced the full repayment and discharge of its unsecured revolving line of credit with Larry Powalisz, the Company's Chief Executive Officer.Adia Med Fully Repays Related-Party Credit Facility, Strengthening Its Financial PositionTo view an enhanced version of this...

Yahoo · Oct 6, 2026

Adia Med Partners with Live Oak Health (dba QCM Biologics) as Distributor and Sells 30% Stake in Adia Labs for $1.5 Million

Winter Park, Florida--(Newsfile Corp. - October 6, 2026) - Adia Med Inc. (OTCQB: ADIA) today announced that it has sold a 30% interest in Adia Labs LLC to Live Oak Health, a stem cell distributor doing business as QCM Biologics, for $1.5 million, and that the sale is paired with a distribution partnership. The Company has filed a Form 8-K related to the transaction.Link to Form 8-K here: Inline Viewer: ADIA MED, INC. 8-K 2026-09-30The transaction includes $1.0 million in cash and a $500,000...

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By